Tumor microenvironment: Modulation by decorin and related molecules harboring leucine-rich tandem motifs

International Journal of Cancer

Volumn 123, Issue 11, 2008, Pages 2473-2479

  Goldoni, Silvia ^a   Iozzo, Renato V ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cancer growth; EGF receptor; IGF I receptor; LRIG1; LRP 1; Small leucine rich proteoglycans; TGF

Indexed keywords

CARBOPLATIN; CHONDROITIN SULFATE; DECORIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; LEUCINE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LUMICAN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; PROTEIN TYROSINE KINASE; SOMATOMEDIN C; SOMATOMEDIN RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; COLON CARCINOMA; DISEASE FREE SURVIVAL; DISEASE MARKER; DOWN REGULATION; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE EXPRESSION; HUMAN; LIPOSARCOMA; LUNG CANCER; METASTASIS; MICROENVIRONMENT; NERVE SHEATH TUMOR; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; SHORT SURVEY; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR XENOGRAFT;

AMINO ACID MOTIFS; ANIMALS; DECORIN; EXTRACELLULAR MATRIX PROTEINS; HUMANS; LEUCINE; NEOPLASMS; PROTEINS; PROTEOGLYCANS; SIGNAL TRANSDUCTION;

EID: 57349175862     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23930     Document Type: Short Survey

References (107)

1. Iozzo RV. Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 1998;67:609-52.
2. Ferdous Z, Wei VM, Iozzo RV, H€o€ok M, Grande-Allen KJ. Decorintransforming growth factor-b interaction regulates matrix organization and mechanical characteristics of three-dimensional collagen matrices. J Biol Chem 2007;282:35887-98.
3. Hocking AM, Shinomura T, McQuillan DJ. Leucine-rich repeat glycoproteins of the extracellular matrix. Matrix Biol 1998;17:1-19.
4. Danielson KG, Baribault H, Holmes DF, Graham H, Kadler KE, Iozzo RV. Targeted disruption of decorin leads to abnormal collagen fibril morphology and skin fragility. J Cell Biol 1997;136:729-43.
5. R€uhland C, Sch€onherr E, Robenek H, Hansen U, Iozzo RV, Bruckner P, Seidler DG. The glycosaminoglycan chain of decorin plays an important role in collagen fibril formation at the early stages of fibrillogenesis. FEBS J 2007;274:4246-55.
6. Ferdous Z, Lazaro LD, Iozzo RV, Höök M, Grande-Allen KJ. Influence of cyclic strain and decorin deficiency on 3D cellularized collagen matrices. Biomaterials 2008;29:2740-8.
7. Bi Y, Stueltens CH, Kilts T, Wadhwa S, Iozzo RV, Robey PG, Chen X-D, Young MF. Extracellular matrix proteoglycans control the fate of bone marrow stromal cells. J Biol Chem 2005;280:30481-9.
8. Brandan E, Cabello-Verrugio C, Vial C. Novel regulatory mechanisms for the proteoglycans decorin and biglycan during muscle formation and muscular dystrophy. Matrix Biol, in press.
9. Järveläinen H, Puolakkainen P, Pakkanen S, Brown EL, Höök M, Iozzo RV, Sage H, Wight TN. A role for decorin in cutaneous wound healing and angiogenesis. Wound Repair Regen 2006;14:443-52.
10. Weis SM, Zimmerman SD, Shah M, Covell JW, Omens JH, Ross J, Jr, Dalton N, Jones Y, Reed CC, Iozzo RV, McCulloch AD. A role for decorin in the remodeling of myocardial infarction. Matrix Biol 2005;24:313-24.
11. Brown EL, Wooten RM, Johnson BJB, Iozzo RV, Smith A, Dolan MC, Guo BP, Weis JJ, Höök M. Resistance to Lyme disease in decorin-deficient mice. J Clin Invest 2001;107:845-52.
12. Schaefer L, Macakova K, Raslik I, Micegova M, Gröne H-J, Schönherr E, Robenek H, Echtermeyer FG, Grässel S, Bruckner P, Schaefer RM, Iozzo RV, et al. Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am J Pathol 2002;160:1181-91.
13. Schaefer L, Mihalik D, Babelova A, Krzyzankova M, Grone HJ, Iozzo RV, Young MF, Seidler DG, Lin G, Reinhardt D, Schaefer RM. Regulation of Fibrillin-1 by biglycan and decorin is important for tissue preservation in the kidney during pressure-induced injury. Am J Pathol 2004;165:383-96.
14. Williams KJ, Qiu G, Usui HK, Dunn SR, McCue P, Bottinger E, Iozzo RV, Sharma K. Decorin deficiency enhances progressive nephropathy in diabetic mice. Am J Pathol 2007;171:1441-50.
15. Iozzo RV. The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. J Biol Chem 1999;274:18843-6.
16. Iozzo RV. The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. Crit Rev Biochem Mol Biol 1997;32:141-74.
17. Chakravarti S, Magnuson T, Lass JH, Jepsen KJ, LaMantia C, Carroll H. Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican. J Cell Biol 1998;141:1277-86.
18. Chakravarti S, Paul J, Roberts L, Chervoneva I, Oldberg A, Birk DE. Ocular and scleral alterations in gene-targeted lumican-fibromodulin double-null mice. Invest Ophthalmol Vis Sci 2003;44:2422-32.
19. Iozzo RV. Tumor stroma as a regulator of neoplastic behavior. Agonistic and antagonistic elements embedded in the same connective tissue. Lab Invest 1995;73:157-60.
20. Weber IT, Harrison RW, Iozzo RV. Model structure of decorin and implications for collagen fibrillogenesis. J Biol Chem 1996;271:31767-70.
21. Keene DR, San Antonio JD, Mayne R, McQuillan DJ, Sarris G, Santoro SA, Iozzo RV. Decorin binds near the C terminus of type I collagen. J Biol Chem 2000;275:21801-4.
22. Reed CC, Iozzo RV. The role of decorin in collagen fibrillogenesis and skin homeostasis. Glycoconj J 2003;19:249-55.
23. Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor-b by the proteoglycan decorin. Nature 1990;346:281-4.
24. Goldoni S, Owens RT, McQuillan DJ, Shriver Z, Sasisekharan R, Birk DE, Campbell S, Iozzo RV. Biologically active decorin is a monomer in solution. J Biol Chem 2004;279:6606-12.
25. Santra M, Reed CC, Iozzo RV. Decorin binds to a narrow region of the epidermal growth factor (EGF) receptor, partially overlapping with but distinct from the EGF-binding epitope. J Biol Chem 2002;277:35671-81.
26. Santra M, Eichstetter I, Iozzo RV. An anti-oncogenic role for decorin: downregulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J Biol Chem 2000;275:35153-61.
27. Csordás G, Santra M, Reed CC, Eichstetter I, McQuillan DJ, Gross D, Nugent MA, Hajnóczky G, Iozzo RV. Sustained down-regulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J Biol Chem 2000;275:32879-87.
28. Santra M, Mann DM, Mercer EW, Skorski T, Calabretta B, Iozzo RV. Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J Clin Invest 1997;100:149-57.
29. De Luca A, Santra M, Baldi A, Giordano A, Iozzo RV. Decorin-induced growth suppression is associated with upregulation of p21, an inhibitor of cyclin-dependent kinases. J Biol Chem 1996;271:18961-5.
30. KIP1. J Biol Chem 2001;276:40687-92.
31. Waf1. Blood 2001;98:2124-33.
32. Iozzo RV, Chakrani F, Perrotti D, McQuillan DJ, Skorski T, Calabretta B, Eichstetter I. Cooperative action of germline mutations in decorin and p53 accelerates lymphoma tumorigenesis. Proc Natl Acad Sci USA 1999;96:3092-7.
33. Bi X, Tong C, Dokendorff A, Banroft L, Gallagher L, Guzman-Hartman G, Augenlicht LH, Iozzo RV, Yang W. Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis 2008;29:1435-40.
34. Schaefer L, Iozzo RV. Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J Biol Chem 2008;283:21305-9.
35. Iozzo RV, Moscatello D, McQuillan DJ, Eichstetter I. Decorin is a biological ligand for the epidermal growth factor receptor. J Biol Chem 1999;274:4489-92.
36. Zhu J-X, Goldoni S, Bix G, Owens RA, McQuillan D, Reed CC, Iozzo RV. Decorin evokes protracted internalization and degradation of the EGF receptor via caveolar endocytosis. J Biol Chem 2005;280:32468-79.
37. Moscatello DK, Santra M, Mann DM, McQuillan DJ, Wong AJ, Iozzo RV. Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J Clin Invest 1998;101:406-12.
38. Zafiropoulos A, Nikitovic D, Katonis P, Tsatsakis A, Karamanos NK, Tzanakakis GN. Decorin-induced growth inhibition is overcome through protracted expression and activation of epidermal growth factor receptors in osteosarcoma cells. Mol Cancer Res 2008;6:785-94.
39. Seidler DG, Goldoni S, Agnew C, Cardi C, Thakur ML, Owens RA, McQuillan DJ, Iozzo RV. Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation. J Biol Chem 2006;281:26408-18.
40. Reed CC, Waterhouse A, Kirby S, Kay P, Owens RA, McQuillan DJ, Iozzo RV. Decorin prevents metastatic spreading of breast cancer. Oncogene 2005;24:1104-10.
41. Schönherr E, Sunderkötter C, Iozzo RV, Schaefer L. Decorin, a novel player in the insulin-like growth factor system. J Biol Chem 2005;280:15767-72.
42. Schaefer L, Tsalastra W, Babelova A, Baliova M, Minnerup J, Sorokin L, Gröne H-J, Reinhardt DP, Pfeilschifter J, Iozzo RV, Schaefer RM. Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-1 receptor and mammalian target of rapamycin. Am J Pathol 2007;170:301-15.
43. Schönherr E, Sunderkotter C, Schaefer L, Thanos S, Grässel S, Oldberg Å, Iozzo RV, Young MF, Kresse H. Decorin deficiency leads to impaired angiogenesis in injured mouse cornea. J Vasc Res 2004;41:499-508.
44. Schönherr E, Levkau B, Schaefer L, Kresse H, Walsh K. Decorin affects endothelial cells by akt-dependent and -independent pathways. Ann N Y Acad Sci 2002;973:149-52.
45. Brandan E, Retamal C, Cabello-Verrugio C, Marzolo M-P. The low density lipoprotein receptor-related protein functions as an endocytic receptor for decorin. J Biol Chem 2006;281:31562-71.
46. Cabello-Verrugio C, Brandan E. A novel modulatory mechanism of transforming growth factor-b signaling through decorin and LRP-1. J Biol Chem 2007;282:18842-50.
47. Li Y, Ahu J, Sun B, Branca M, Tang Y, Foster W, Xiao X, Huard J. Decorin gene transfer promotes muscle cell differentiation and muscle regeneration. Mol Ther 2007;15:1616-22.
48. Nishimura T, Nozu K, Kishioka Y, Wakamatsu J, Hattori A. Decorin expression in quiescent myogenic cells. Biochem Biophys Res Commun 2008;370:383-7.
49. Adany R, Heimer R, Caterson B, Sorrell JM, Iozzo RV. Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. Hypomethylation of PG-40 gene correlates with increased PG-40 content and mRNA levels. J Biol Chem 1990;265:11389-96.
50. Brézillon S, Venteo L, Ramont L, D'Onofrio M-F, Perreau C, Pluot M, Maquart F-X, Wegrowski Y. Expression of lumican, a small leucine-rich proteoglycan with antitumour activity, in human malignant melanoma. Clin Exp Dermatol 2007;32:405-16.
51. Järveläinen HT, Iruela-Arispe ML, Kinsella MG, Sandell LJ, Sage EH, Wight TN. Expression of decorin by sprouting bovine aortic endothelial cells exhibiting angiogenesis in vitro. Exp Cell Res 1992;203:395-401.
52. Nelimarkka L, Kainulainen V, Schönherr E, Moisander S, Jortikka M, Lammi M, Elenius K, Jalkanen M, Järveläinen HT. Expression of small extracellular chondroitin/dermatan sulfate proteoglycans is differentially regulated in human endothelial cells. J Biol Chem 1997;272:12730-7.
53. Nelimarkka L, Salminen H, Kuopio T, Nikkari S, Ekfors T, Laine J, Pelliniemi L, Järveläinen H. Decorin is produced by capillary endothelial cells in inflammation-associated angiogenesis. Am J Pathol 2001;158:345-53.
54. Schönherr E, O'Connell BC, Schittny J, Robenek H, Fastermann D, Fisher LW, Plenz G, Vischer P, Young MF, Kresse H. Paracrine or virus-mediated induction of decorin expression by endothelial cells contributes to tube formation and prevention of apoptosis in collagen lattices. Eur J Cell Biol 1999;78:44-55.
55. Albig AR, Roy TG, Becenti DJ, Schiemann WP. Transcriptome analysis of endothelial cell gene expression induced by growth on Matrigel matrices: identification and characterization of MAGP-2 and lumican as novel regulators of angiogenesis. Angiogenesis 2007;10:197-216.
56. Fiedler LR, Schönherr E, Waddington R, Niland S, Seidler DG, Aeschlimann D, Eble JA. Decorin regulates endothelial cell motility on collagen I through activation of Insulin-like grwoth factor I receptor and modulation of a2b1 integrin activity. J Biol Chem 2008;283:17406-15.
57. de Lange Davies C, Melder RJ, Munn LL, Mouta-Carreira C, Jain RK, Boucher Y. Decorin inhibits endothelial migration and tube-like structure formation: role of thrombospondin-1. Microvasc Res 2001;62:26-42.
58. Grant DS, Yenisey C, Rose RW, Tootell M, Santra M, Iozzo RV. Decorin suppresses tumor cell-mediated angiogenesis. Oncogene 2002;21:4765-77.
59. Sulochana KN, Fan H, Jois S, Subramanian V, Sun F, Kini RM, Ge R. Peptides derived from human decorin leucine-rich repeat 5 inhibit angiogenesis. J Biol Chem 2005;280:27935-48.
60. Petit AMV, Rak J, Hung M-C, Rockwell P, Goldstein N, Fendly B, Kerbel RS. Neutralizing antibodies against epidermal growth factor and Erb-2/neu receptor tyrosine kinases down-regulated vascular endothelial growth factor production by tumor cells in vitro and in vivo. Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997;151:1523-30.
61. Salomäki HH, Sainio AO, Söderström M, Pakkanen S, Laine J, Järveläinen HT. Differential expression of decorin by human malignant and benign vascular tumors. J Histochem Cytochem 2008;56:639-46.
62. Li X, Pennisi A, Yaccoby S. Role of decorin in the antimyeloma effects of osteoblasts. Blood 2008;112:159-68.
63. Crnogorac-Jurcevic T, Efthimiou E, Capelli P, Blaveri E, Baron A, Terris B, Jones M, Tyson K, Bassi C, Scarpa A, Lemoine NR. Gene expression profiles of pancreatic cancer and stromal desmoplasia. Oncogene 2001;20:7437-46.
64. Köninger J, Giese T, di Mola FF, Wente MN, Esposito I, Bachem MG, Giese NA, Büchler MW, Friess H. Pancreatic tumor cells influence the composition of the extracellular matrix. Biochem Biophys Res Commun 2004;322:943-9.
65. McDoniels-Silvers AL, Nimri CF, Stoner GD, Lubet RA, You M. Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas. Clin Cancer Res 2002;8:1127-38.
66. Banerjee AG, Bhattacharyya I, Lydiatt WM, Vishwnatha JK. Aberrant expression and localization of decorin in human oral dysplasia and squamous cell carcinoma. Cancer Res 2003;63:7769-76.
67. Nash MA, Deavers MT, Freedman RS. The expression of decorin in human ovarian tumors. Clin Cancer Res 2002;8:1754-60.
68. Newton TR, Parsons PG, Lincoln DJ, Cummings MC, Wyld DK, Webb PM, Green AC, Boyle GM. Expression profiling correlates with treatment response in women with advanced serous epithelial ovarian cancer. Int J Cancer 2006;119:875-83.
69. Troup S, Njue C, Kliewer EV, Parisien M, Roskelley C, Chakravarti S, Roughley PJ, Murphy LC, Watson PH. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res 2003;9:207-14.
70. Matsumine A, Shintani K, Kusuzaki K, Matsubara T, Satonaka H, Wakabayashi T, Iino T, Uchida A. Expression of decorin, a small leucine-rich proteoglycan, as a prognostic factor in soft tissue tumors. J Surg Oncol 2007;96:411-18.
71. Theocharis AD. Human colon adenocarcinoma is associated with specific post-traslational modifications of versican and decorin. Biochim Biophys Acta 2002;1588:165-72.
72. Theocharis AD, Vynios DH, Papageorgakopoulou N, Skandalis SS, Theocharis DA. Altered content composition and structure of glycosaminoglycans and proteoglycans in gastric carcinoma. Int J Biochem Cell Biol 2003;35:376-90.
73. Skandalis SS, Kletsas D, Kyriakopoulou D, Stavropoulos D, Theocharis DA. The greatly increased amounts of accumulated versican and decorin with specific post-translational modifications may be closely associated with the malignant phenotype of pancreatic cancer. Biochim Biophys Acta 2006;1760:1217-25.
74. Merle B, Durussel L, Delmas PD, Clézardin P. Decorin inhibits cell migration through a process requiring its glycosaminoglycan side chain. J Cell Biochem 1999;75:538-46.
75. Adany R, Iozzo RV. Hypomethylation of the decorin proteoglycan gene in human colon cancer. Biochem J 1991;276:301-6.
76. Nash MA, Loercher AE, Freedman RS. In vitro growth inhibition of ovarian cancer cells by decorin: synergism of action between decorin and carboplatin. Cancer Res 1999;59:6192-6.
77. Köninger J, Giese NA, di Mola FF, Berberat P, Giese T, Esposito I, Bachem MG, Buchler MW, Friess H. Overexpressed decorin in pancreatic cancer: potential tumor growth inhibition and attenuation of chemotherapeutic action. Clin Cancer Res 2004;10:4776-83.
78. Tralhão JG, Schaefer L, Micegova M, Evaristo C, Schönherr E, Kayal S, Veiga-Fernandes H, Danel C, Iozzo RV, Kresse H, Lemarchand P. In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer. FASEB J 2003;17:464-6.
79. Reed CC, Gauldie J, Iozzo RV. Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene 2002;21:3688-95.
80. Pucci-Minafra I, Cancemi P, Cara GD, Minafra L, Feo S, Fortino A, Tira ME, Tenni R, Martini D, Ruggeri A, Minafra S. Decorin transfection induces proteomic and phenotypic modulation in breast cancer cells 8701-BC. Connect Tissue Res 2008;49:30-41.
81. Shintani K, Matsumine A, Kusuzaki K, Morikawa J, Matsubara T, Wakabayashi T, Araki K, Satonaka H, Wakabayashi H, Lino T, Uchida A. Decorin suppresses lung metastases of murine osteosarcoma. Oncol Rep 2008;19:1533-9.
82. Biglari A, Bataille D, Naumann U, Weller M, Zirger J, Castro MG, Lowenstein PR. Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Ther 2004;11:721-32.
83. Goldoni S, Seidler DG, Heath J, Fassan M, Baffa R, Thakur ML, Owens RA, McQuillan DJ, Iozzo RV. An anti-metastatic role for decorin in breast cancer. Am J Pathol 2008;173:844-55.
84. Santra M, Skorski T, Calabretta B, Lattime EC, Iozzo RV. De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc Natl Acad Sci USA 1995;92:7016-20.
85. Nilsson J, Vallbo C, Guo D, Golovleva I, Hallberg B, Henriksson R, Hedman H. Cloning, characterization, and expression of human LIG1. Biochem Biophys Res Commun 2001;284:1155-61.
86. Ghiglione C, Carraway KL, III, Amundadottir LT, Boswell RE, Perrimon N, Duffy JB. The transmembrane molecule kekkon 1 acts in a feedback loop to negatively regulate the activity of the Drosophila EGF receptor during oogenesis. Cell 1999;96:847-56.
87. Ghiglione C, Amundadottir L, Andresdottir M, Bilder D, Diamonti JA, Noselli S, Perrimon N, Carraway KL, III. Mechanism of inhibition of the Drosophila and mammalian EGF receptors by the transmembrane protein Kekkon 1. Development 2003;130:4483-93.
88. Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway KL, III, Sweeney C. The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 2004;279:47050-6.
89. Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, Amariglio N, Henriksson R, Rechavi G, Hedman H, Wides R, Yarden Y. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 2004;23:3270-81.
90. Jensen KB, Watt FM. Single-cell expression profiling of human epidermal stem and transit-amplifying cells: lrig1 is a regulator of stem cell quiescence. Proc Natl Acad Sci USA 2006;103:11958-63.
91. Shattuck DL, Miller JK, Laederich M, Funes M, Petersen H, Carraway KLI, Sweeney C. LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol 2007;27:1934-46.
92. Goldoni S, Iozzo RA, Kay P, Campbell S, McQuillan A, Agnew C, Zhu J-X, Keene DR, Reed CC, Iozzo RV. A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity. Oncogene 2007;26:368-81.
93. Guo D, Nilsson J, Haapasalo H, Raheem O, Bergenheim T, Hedman H, Henriksson R. Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathol 2006;111:238-46.
94. Tanemura A, Nagasawa T, Inui S, Itami S. LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. Dermatol Surg 2005;31:423-30.
95. Ljuslinder I, Golovleva I, Palmqvist R, Öberg Å, Stenling R, Jonsson Y, Hedman H, Henriksson R, Malmer B. LRIG1 expression in colorectal cancer. Acta Oncol 2007;46:1118-22.
96. Lindström AK, Ekman K, Stendahl U, Tot T, Henriksson R. LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumor markers, sex steroid hormones, and smoking. Int J Gynecol Cancer 2008;18:312-17.
97. Suzuki Y, Miura H, Tanemura A, Kobayashi K, Kondoh G, Sano S, Ozawa K, Inui S, Nakata A, Takagi T, Tohyama M, Yoshikawa K, Itami S. Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia. FEBS Lett 2002;521:67-71.
98. Karlsson T, Mark EB, Henriksson R, Hedman H. Redistribution of LRIG proteins in psoriasis. J Invest Dermatol 2008;128:1192-5.
99. Vassar R, Fuchs E. Transgenic mice provide new insights into the role of TGF-alpha during epidermal development and differentation. Genes Dev 1991;5:714.
100. Cook PW, Piepkorn M, Clegg CH, Plowman GD, DeMay JM, Brown JR, Pittelkow MR. Transgenic expression of the human amphiregulin gene induces a psoriasis-like phenotype. J Clin Invest 1997;100:2286-94.
101. Ledda F, Bieraugel O, Fard SS, Vilar M, Paratcha G. Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. J Neurosci 2008;28:39-49.
102. Li Y, Aoki T, Mori Y, Ahmad M, Miyamori H, Takino T, Sato H. Cleavage of lumican by membrane-type matrix metalloprotease-1 abrogates this proteoglycan-mediated suppression of tumor cell colony formation in soft agar. Cancer Res 2004;64:7058-64.
103. Vij N, Roberts L, Joyce S, Chakravarti S. Lumican suppresses cell proliferation and aids Fas-Fas ligand mediated apoptosis: implications in the cornea. Exp Eye Res 2004;78:957-71.
104. Nikitovic D, Berdiaki A, Zfiropoulos A, Katonis P, Tsatsakis A, Karamanos N, Tzanakakis GN. Lumican expression is positively correlated with the differentiation and negatively with the growth of human osteosarcoma cells. FEBS J 2008;275:350-61.
105. Vuillermoz B, Khoruzhenko A, D'Onofrio MF, Ramont L, Venteo L, Perreau C, Antonicelli F, Maquart FX, Wegrowski Y. The small leucine-rich proteoglycan lumican inhibits melanoma progression. Exp Cell Res 2004;296:294-306.
106. Leygue E, Snell L, Dotzlaw H, Troup S, Hiller-Hitchcock T, Murphy LC, Roughley PJ, Watson PH. Lumican and decorin are differentially expressed in human breast carcinoma. J Pathol 2000;192:313-20.
107. Seya T, Tanaka N, Shinji S, Yokoi K, Koizumi M, Teranishi N, Yamashita K, Tajiri T, Ishiwata T, Naito Z. Lumican expression in advanced colorectal cancer with nodal metastasis correlates with poor prognosis. Oncol Rep 2006;16:1225-30.